[Dilip Davda] After showing dismal performances for FY20 and FY21, it marked a bumper turnover and net profits, which appears to be a window dressing in a pre-IPO year. DPL is just a trader in pharmachem. Since it is operating in a highly competitive and fragmented segment, the sustainability of such performance is a major concern. Based on such super profits also the issue is aggressively priced. There is no harm in ignoring such a pricy bet. Read detail review...

Dipna Pharmachem IPO Review by Members

Dipna Pharmachem IPO Reviews, analysis and views by popular members. Read Dipna Pharmachem Ltd. IPO reviews by retail investors to find recommended ipo to buy.

Dipna Pharmachem IPO Review Summary by Members

Review By	Apply	May Apply	Neutral	Avoid
Count	0	0	0	0
%	0.00	0.00	0.00	0.00

Member	Review
No recommendation found. Be the first to post the recommendation.

Manage Recommendations

Note:

The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
We reserve the right to remove any objectionable post without providing a reason.

Dipna Pharmachem IPO Review & Recommendations

Dipna Pharmachem IPO Review Summary from brokers and analysts

Dipna Pharmachem IPO Review by Dilip Davda (Avoid)

Dipna Pharmachem IPO Review by Members

Dipna Pharmachem IPO Review Summary by Members

Read more about Dipna Pharmachem IPO